SR 8541A
Alternative Names: SR-8541ALatest Information Update: 14 Jun 2024
At a glance
- Originator Stingray Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Ectonucleotide pyrophosphatase phosphodiesterase 1 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 Apr 2024 Pharmacokinetics and adverse events data from a phase I trial in Solid tumours presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
- 12 Oct 2023 Phase-I clinical trials in Solid tumours (Late-stage disease, Metastatic disease) in Australia (PO) (NCT06063681)
- 09 Oct 2023 Pharmacodynamics data from preclinical studies in cancer released by Stingray Therapeutics